Affibody molecules are small (6.5-kDa) affinity proteins based on a three-helix bundle
domain framework. Since their introduction 20 years ago as an alternative to antibodies for …

Tumor cells overexpress surface markers which are absent from normal cells. These tumor-
restricted antigenic signatures are a fundamental basis for distinguishing on-target from off …

Liposomal formulations entrapping a vast number of molecules have improved cancer
therapies overcoming certain pharmacokinetic (PK) and pharmacodynamic limitations, many …

Since the emergence of cancer nanomedicine, researchers have had intense interest in
developing nanoparticles (NPs) that can specifically target diseased sites while avoiding …

Gastrointestinal cancer is a common malignant tumor with a high incidence worldwide.
Despite continuous improvements in diagnosis and treatment strategies, the overall …

Initially emerging as a highly innovative concept in the late 1990s, the concept of creating
novel binding reagents based on stable protein scaffolds from outside the immunoglobulin …

Non-immunoglobulin scaffolds represent a proven group of small affinity proteins that can be
engineered in vitro to similar affinity and potency as monoclonal antibodies. Several novel …

Overexpression of human epidermal growth factor receptor type 3 (HER3) is associated with
tumour cell resistance to HER-targeted therapies. Monoclonal antibodies (mAbs) targeting …

Recombinant elastin-like polypeptides (ELPs) have emerged as an attractive nanoplatform
for drug delivery due to their tunable genetically encoded sequence, biocompatibility, and …

Epstein-Barr virus (EBV) infection is closely linked to several human malignancies including
endemic Burkitt's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinomas (NPC) …